# Therapy With Asunaprevir, Daclatasvir, Ribavirin and Pegylated Interferon Alpha-2a in HCV Genotype 4-infected Patients Who Have Failed to a Previous Therapy With Peg-Interferon/Ribavirin (ANRS HC32 QUATTRO)

> **NCT02107365** · PHASE2 · COMPLETED · sponsor: **ANRS, Emerging Infectious Diseases** · enrollment: 60 (actual)

## Conditions studied

- Hepatitis C Virus Genotype 4 Infection

## Interventions

- **DRUG:** Asunaprevir
- **DRUG:** Daclatasvir
- **DRUG:** Ribavirin
- **DRUG:** Pegylated Interferon alpha-2a

## Key facts

- **NCT ID:** NCT02107365
- **Lead sponsor:** ANRS, Emerging Infectious Diseases
- **Sponsor class:** OTHER_GOV
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2013-11
- **Primary completion:** 2015-02
- **Final completion:** 2015-04
- **Target enrollment:** 60 (ACTUAL)
- **Last updated:** 2026-04-13

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02107365

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02107365, "Therapy With Asunaprevir, Daclatasvir, Ribavirin and Pegylated Interferon Alpha-2a in HCV Genotype 4-infected Patients Who Have Failed to a Previous Therapy With Peg-Interferon/Ribavirin (ANRS HC32 QUATTRO)". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT02107365. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*